Condition

Nonalcoholic Steatohepatitis

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 31 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials31
Recruiting3
Common interventions25
Lead sponsors shown15
Advertisement

Clinical trials

31 shown
Screening and Follow-up in Patients With HIV Infection Combined With Metabolic Associated Fatty Liver DiseaseNCT05330923 · 2022-01-01
RECRUITING
Low-Dose Pioglitazone in Patients With NASH (AIM 2)NCT04501406 · 2020-12-15
RECRUITING
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin ResistanceNCT05165706 · 2019-01-31
RECRUITING
Bariatric Embolization of Arteries for the Treatment of Nonalcoholic SteatohepatitisNCT02933554 · 2025-12-01
NOT_YET_RECRUITING
Conditionally Increased Output (CIO) Enhanced Ultrasound SystemNCT05792423 · 2023-06-30
COMPLETED
A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASHNCT03970031 · 2022-06-01
UNKNOWN
Metabolic Pathology of Pediatric NAFLDNCT05430178 · 2022-05-25
UNKNOWN
Efficacy and Safety of Guanabenz for Nonalcoholic Fatty Liver DiseaseNCT05084404 · 2021-10-29
UNKNOWN
Clinical Outcomes From Enhanced SCREENing Strategies for NASH in Type 2 Diabetes (SCREEN NASH T2D)NCT05029583 · 2021-08-11
UNKNOWN
Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 DiabetesNCT04595474 · 2021-01-14
ACTIVE_NOT_RECRUITING
ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and TolerabilityNCT04561245 · 2020-11-10
COMPLETED
To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult ParticipantsNCT04389775 · 2020-03-29
COMPLETED
De Novo Lipogenesis in Severity of NAFLDNCT03683589 · 2019-02-01
COMPLETED
A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)NCT03656744 · 2018-11-26
COMPLETED
A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious PsoriasisNCT03329885 · 2017-11-02
TERMINATED
The Liver Health Study for Patients with NAFLDNCT03151798 · 2017-08-09
COMPLETED
A Reduced-carbohydrate Diet High in Monounsaturated Fats in Type 2 DiabetesNCT03068078 · 2016-11-01
COMPLETED
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 DiabetesNCT02769091 · 2016-09-30
WITHDRAWN
Pathogenesis of Non-alcoholic Steatohepatitis and Liver Regeneration After Bariatric SurgeryNCT02792634 · 2016-06-01
UNKNOWN
Controlled Trial of WLS vs. CLI for Severely Obese Adolescents With NASHNCT02412540 · 2015-04-23
COMPLETED
Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected PatientsNCT02210715 · 2015-03-01
COMPLETED
Impact of Bariatric Surgery on Nonalcoholic Fatty Liver DiseaseNCT01828528 · 2013-04-01
COMPLETED
Non Alcoholic Fatty Liver Disease and Coronary Heart Disease in Type 2 Diabetes PatientsNCT04462081 · 2013-01-01
COMPLETED
Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With LipodystrophyNCT01679197 · 2012-10-08
COMPLETED
Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 DiabetesNCT01399645 · 2011-05-01
COMPLETED
Sitagliptin for the Treatment of Non-alcoholic Steatohepatitis in Patients With Type 2 DiabetesNCT01260246 · 2010-12-01
TERMINATED
Liraglutide Efficacy and Action in Non-Alcoholic SteatohepatitisNCT01237119 · 2010-08-01
COMPLETED
Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of TreatmentNCT01002547 · 2010-06-24
COMPLETED
University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial)NCT00994682 · 2008-12-01
COMPLETED
Effect of Dietary and Life Style Modification on Post Liver Transplant ObesityNCT00878592 · 2008-10-01
TERMINATED
Treatment of Nonalcoholic Steatohepatitis With PioglitazoneNCT00013598 · 2001-03-01
COMPLETED

Common interventions

PlaceboDRUG5PioglitazoneDRUG3PlaceboOTHER3ALT-801DRUG1BMS-986251DRUG1Cohort ADRUG1Cohort BDRUG1Comprehensive Lifestyle InterventionBEHAVIORAL1Continue usual antiretroviral therapyOTHER1De novo lipogenesis testOTHER1Dietary and life style modificationBEHAVIORAL1Dietary Intervention Mediterranean Low Carbohydrate DietBEHAVIORAL1Dietary Intervention Standard Low Carbohydrate DietBEHAVIORAL1Dietary Intervention Standard Low Fat DietBEHAVIORAL1Embospheres MicrospheresDEVICE1Experimental: 4 mg/day of WY-8678 (guanabenz acetate)DRUG1Experimental: 8 mg/day of WY-8678 (guanabenz acetate)DRUG1GE ultrasound system with increased acoustic output settingsDEVICE1Gluconeogenesis testOTHER1HTD1801DRUG1Isentress.DRUG1LiraglutideDRUG1Liraglutide-metformin vs insulin-metforminDRUG1Liraglutide-placeboOTHER1Liver Quantitative UltrasoundDEVICE1

Leading sponsors

University of Florida 2 University of Missouri-Columbia 2 Altimmune, Inc. 1 Bristol-Myers Squibb 1 Centre hospitalier de l'Université de Montréal (CHUM) 1 Children's Hospital Medical Center, Cincinnati 1 Cirius Therapeutics, Inc. 1 HighTide Therapeutics (Hong Kong) Limited 1 Joslin Diabetes Center 1 Keith Pereira, MD: 1 LMC Diabetes & Endocrinology Ltd. 1 London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's 1 Massachusetts General Hospital 1 McGill University Health Centre/Research Institute of the McGill University Health Centre 1 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 1

Trial status mix

COMPLETED17
UNKNOWN5
RECRUITING3
TERMINATED3
ACTIVE_NOT_RECRUITING1
NOT_YET_RECRUITING1
WITHDRAWN1

Phase mix

NA10
PHASE29
PHASE13
PHASE43
PHASE31
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.